We are joined by Othman Al-Sawaf at EHA 2019 to discuss his presentation on high efficacy of venetoclax plus obinutuzumab in patients with complex karyotype (CKT) and chronic lymphocytic leukemia (CLL): A prospective analysis from the CLL14 trial.
Questions
1. Could you tell us a little about complex karyotype (CKT) in chronic lymphocytic leukemia (CLL) and its impact on prognosis? (0:05)
2. What are the limitations of current therapeutic options for CLL CKT patients? (1:13)
3. What is the rationale for the use of venetoclax plus obinutuzumab in this treatment setting? (2:00)
4. What were the efficacy and safety findings of your recent analysis of the CLL14 trial? (3:15)
5. Which patients are most likely to respond to this combination and in which patients is it contraindicated? (4:15)
Othman Al-Sawaf has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
